Stimulating T4 Implementation Research to Optimize Integration of Proven-effective Interventions for Heart, Lung, and Blood Diseases and Sleep Disorders into Practice (STIMULATE-2) (R61/R33 Clinical Trial Required) | RFA HL 21 011

Opportunity Information: Apply for RFA HL 21 011

The NIH grant opportunity "Stimulating T4 Implementation Research to Optimize Integration of Proven-effective Interventions for Heart, Lung, and Blood Diseases and Sleep Disorders into Practice (STIMULATE-2)" (Funding Opportunity Number RFA-HL-21-011) is a discretionary grant program created to speed up the real-world delivery of proven, evidence-based interventions for heart, lung, and blood diseases and sleep disorders (often abbreviated as HLBS). The central problem it targets is a persistent "translation gap": even when strong clinical or public health evidence exists, those interventions frequently do not get adopted broadly, implemented well, or sustained over time in routine care, public health, or community settings. This FOA is meant to push beyond generating more efficacy data and instead focus on how to reliably integrate what already works into everyday practice so it reaches more people and improves health outcomes at scale.

This announcement is specifically oriented to late-stage translation and implementation research, described here as T4 research. In practical terms, T4 is about achieving sustainable uptake and routine use of proven-effective interventions in real-world settings, rather than testing whether the intervention itself works under controlled conditions. Applicants are expected to use established implementation science frameworks to design, refine, and test implementation strategies, meaning the "how" of rolling out an evidence-based practice (EBP). The emphasis is on strategies that can last beyond the life of the research grant (so they are not dependent on temporary outside resources) and that can be transferred or adapted by other organizations and stakeholder groups.

The FOA supports pragmatic, milestone-driven projects that are single-site and biphasic, using the R61/R33 funding mechanism. The biphasic structure generally implies an early phase focused on planning, preparation, and meeting defined milestones (R61), followed by a second phase focused on executing and evaluating the implementation approach (R33) once milestones are achieved. The work is characterized as late-stage implementation research rather than early discovery, and it is designed to be practical and decision-relevant for real-world systems. The funding opportunity explicitly requires a clinical trial, indicating that the proposed research must include a prospective, systematic evaluation of an intervention or strategy, consistent with NIH clinical trial definitions, but here the intervention being tested is typically the implementation strategy (or strategies) used to improve adoption and sustained use of an already proven EBP.

A key objective is to identify and test adaptable implementation strategies that increase scale-up and sustainable use of EBPs for preventing and/or managing HLBS conditions. "Adaptable" matters because health systems, clinics, community organizations, and public health agencies vary widely in staffing, workflows, patient populations, technology, and resources. Strong applications under this FOA would therefore focus on implementation approaches that can be adjusted to local context while still preserving the core elements needed to succeed, with the broader goal of making the resulting strategies useful to many end-users rather than only the original study site.

In addition to testing implementation strategies, the FOA places clear value on developing and disseminating an implementation strategy plan that others can reuse. This can include producing practical tools, playbooks, protocols, and potentially reusable infrastructure that helps future adopters replicate success. The announcement even gives an example of reusable infrastructure such as national standards for data extraction and interoperability, reflecting an interest in solutions that help organizations implement EBPs more efficiently through better data systems, measurement, and information exchange. In other words, the program is not only about learning what works at one site, but also about packaging the strategy so that health systems, public health organizations, and community stakeholders elsewhere can adapt it and implement it successfully.

Eligibility is broad and includes many types of domestic organizations and government entities. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations other than federally recognized tribal governments; public housing authorities and Indian housing authorities; nonprofit organizations (both 501(c)(3) and non-501(c)(3) categories) other than institutions of higher education; for-profit organizations other than small businesses; and small businesses. The FOA also calls out additional eligible applicant types and community-centered institutions, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions. This broad eligibility aligns with the program's focus on implementation in diverse real-world settings where patients and communities actually receive care and services.

At the same time, the FOA draws a firm line on foreign participation. Non-domestic (non-U.S.) entities and non-domestic (non-U.S.) institutions are not eligible to apply. U.S. organizations may include non-domestic components, but "foreign components" as defined in the NIH Grants Policy Statement are not allowed. This means the work must remain within NIH's domestic scope, with limits on conducting substantive project elements abroad.

From an administrative standpoint, the opportunity is offered by the National Institutes of Health and is associated with CFDA numbers 93.233, 93.837, 93.838, 93.839, and 93.840, reflecting NIH programs spanning heart and vascular, lung, blood, and sleep-related research portfolios. The FOA was created on 2019-11-19 and had an original closing date of 2020-07-01. The listed award ceiling is $485,000, which indicates the maximum award amount referenced in the opportunity summary (applicants typically still need to verify detailed budget limits and project period rules in the full FOA text). Expected awards are not specified in the provided excerpt.

Overall, STIMULATE-2 is best understood as an NIH implementation science program aimed at the "last mile" problem in HLBS health: taking interventions that are already proven effective and figuring out how to get them adopted broadly, implemented consistently, and maintained over time in clinics, public health systems, and community settings. The program prioritizes rigorous, framework-guided, pragmatic evaluation of implementation strategies, clear milestones, and products that make successful strategies replicable and scalable for other stakeholders long after the grant ends.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Stimulating T4 Implementation Research to Optimize Integration of Proven-effective Interventions for Heart, Lung, and Blood Diseases and Sleep Disorders into Practice (STIMULATE-2) (R61/R33 Clinical Trial Required)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.233, 93.837, 93.838, 93.839, 93.840.
• This funding opportunity was created on 2019-11-19.
• Applicants must submit their applications by 2020-07-01. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $485,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA HL 21 011

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: